frontier-banner
Frontiers
Home>Frontiers>

Nature Medicine | Impact of Broadly Neutralizing Antibody Combination Therapy During Analytical Treatment Interruption on Viral Rebound and Reservoir Dynamics in Early HIV Infection

Nature Medicine | Impact of Broadly Neutralizing Antibody Combination Therapy During Analytical Treatment Interruption on Viral Rebound and Reservoir Dynamics in Early HIV Infection
--

This study elucidates the critical mechanism of synergy between endogenous antibodies within the HIV reservoir and exogenous broadly neutralizing antibodies (bNAbs), providing direct experimental evidence for optimizing reservoir clearance strategies and designing combination immunotherapies.

 

Literature Overview

This article, titled "Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial," published in Nature Medicine, systematically explores the changes in viral rebound kinetics, reservoir composition, and antibody sensitivity following intervention with long-acting bNAbs (3BNC117-LS and 10-1074-LS) in HIV-infected individuals who initiated antiretroviral therapy (ART) early. Through a randomized controlled trial, the study deeply analyzes the correlates of viral control and viral escape mechanisms after treatment interruption.

Background Knowledge

This research aims to address the core challenge of HIV cure: the persistence of the latent viral reservoir. Although early ART significantly reduces the reservoir burden, the virus rebounds rapidly upon discontinuation. Current reservoir research faces two major bottlenecks: first, the difficulty in precisely quantifying the replication-competent intact reservoir; second, the lack of effective means to clear latent cells or sustainably suppress viral rebound. The focus of this study lies in utilizing long-acting bNAbs to provide sustained immune pressure during analytical treatment interruption (ATI), investigating how host endogenous antibody responses and exogenous antibody therapy jointly shape viral rebound characteristics, and whether this combined pressure can accelerate reservoir decay or induce long-term remission.

 

 

Research Methods and Experiments

The authors employed a randomized, double-blind, placebo-controlled Phase II clinical trial design (the RIO trial), enrolling 68 adult males with early HIV infection who had initiated ART. The experimental group received infusions of long-acting bNAbs (3BNC117-LS and 10-1074-LS), while the control group received a placebo, followed by ART interruption for both groups. The research team utilized digital droplet PCR (ddPCR) and quadruplex probe PCR (Q4PCR) to precisely quantify intact and defective HIV-1 proviral reservoirs in CD4+ T cells at baseline and prior to treatment interruption. Furthermore, single-genome amplification was used to obtain env sequences at baseline and during viral rebound to construct pseudoviruses for neutralization sensitivity testing, assessing changes in viral sensitivity to autologous antibodies and therapeutic antibodies.

Key Conclusions and Perspectives

  • Significant Delay in Viral Rebound: Compared to the placebo group, the bNAb-treated group showed a significantly prolonged median time to ART restart (45.4 weeks vs. 4.6 weeks), with 24% of participants achieving 96 weeks of ART-free control, indicating that long-acting antibodies can effectively delay viral rebound.
  • Selective Viral Escape: Rebound viruses showed significant selection for resistance to 10-1074-LS, but not to 3BNC117-LS, suggesting that in combination therapy, the escape pressure from 10-1074 is more pronounced, while 3BNC117 concentrations may be insufficient during rebound.
  • Correlation Between Autologous Antibodies and Viral Sensitivity: Higher baseline sensitivity of the viral reservoir to autologous neutralizing antibodies, and greater sensitivity to 10-1074, correlated with later viral rebound times, highlighting the importance of the synergy between host endogenous immune responses and exogenous therapy.
  • Changes in Reservoir Dynamics: The bNAb-treated group observed a significant reduction in the intact proviral reservoir during follow-up (half-life approximately 36 weeks), while the defective reservoir remained unchanged, suggesting that antibody therapy may promote the clearance of infected cells or alter reservoir kinetics.

Research Significance and Prospects

These findings have profound implications for HIV functional cure strategies. First, they confirm that combining host pre-existing immunity (autologous antibodies) with exogenous bNAbs is key to extending viral control, providing theoretical support for the future combined application of vaccine design and antibody therapies. Second, the viral escape patterns revealed suggest that when developing long-acting antibody combinations, antibody ratios must be optimized to overcome the risk of single-antibody escape. Finally, the observed decay of the intact reservoir provides a new biomarker for evaluating the efficacy of reservoir clearance therapies, driving deeper exploration into the mechanisms of latent virus clearance.

 

 

Conclusion

In-depth analysis of the RIO trial indicates that for HIV-infected individuals who initiated treatment early, long-acting broadly neutralizing antibodies not only significantly delay viral rebound but also alter the composition and kinetics of the viral reservoir through immune pressure. The study emphasizes that the synergy between host endogenous antibody levels and exogenous antibody therapy is a critical factor in achieving long-term viral control. This finding represents a significant step from laboratory mechanistic research to clinical translation, suggesting that future HIV cure strategies should place greater emphasis on the combined intervention of stimulating host immunity and passive immunity. By precisely selecting reservoir subpopulations sensitive to specific antibodies and optimizing antibody combinations to block escape pathways, it is hoped to provide long-term remission solutions without lifelong medication for more patients, fundamentally transforming the HIV care system.

 

Reference:
Marcilio J Fumagalli, Anna Kaczynska, Marius Allombert, Sarah Fidler, and Michel C Nussenzweig. Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial. Nature Medicine.
ΔΔG Upon Mutation(RDE)
A flow-based generative model (named Rotamer Density Estimator, RDE) estimates the probability distribution of conformation , uses entropy as the measure of flexibility and predict the binding ∆∆G.